so your information would indicate that we didn't change to ASOs for the eye because we already had an interested party or someone who requested that. It seems once we have the results then we hope to attract some interest or "set up our shop front" and hopefully find a customer? Either way still a smart move to target the eye i guess as it lowers the problems we were apparently having trying to be cell specific.
It would be interesting to know if fpp are still viable for any other body parts or organs, or have they found that there is no real chance of being able to target specific cells from systemic body injection. Surely there must be some application if used with more localised or targetted application but who knows. Even if they can only target the eye now i guess it still offers economic possibilities.
just thinking out loud i wonder if they have considered anything that could be vapourised and inhaled and work on the lungs, using same principle of penetrating whatever it reaches first.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)